Brief Definitive Report

Protection from Respiratory Virus Infections Can Be Mediated by Antigen-specific CD4+ T Cells That Persist in the Lungs

By Robert J. Hogan, Weimin Zhong, Edward J. Usherwood, Tres Cookenham, Alan D. Roberts, and David L. Woodland

From the Trudeau Institute, Saranac Lake, New York 12983

Abstract

Although CD4+ T cells have been shown to mediate protective cellular immunity against respiratory virus infections, the underlying mechanisms are poorly understood. For example, although phenotypically distinct populations of memory CD4+ T cells have been identified in different secondary lymphoid tissues, it is not known which subpopulations mediate protective cellular immunity. In this report, we demonstrate that virus-specific CD4+ T cells persist in the lung tissues and airways for several months after Sendai virus infection of C57BL/6 mice. A large proportion of these cells possess a highly activated phenotype (CD44hi, CD62Llo, CD43hi, and CD25hi) and express immediate effector function as indicated by the production of interferon γ after a 5-h re-stimulation in vitro. Furthermore, intratracheal adoptive transfer of lung memory cells into β2m-deficient mice demonstrated that lung-resident virus-specific CD4+ T cells mediated a substantial degree of protection against secondary virus infection. Taken together, these data demonstrate that activated memory CD4+ T cells persisting at mucosal sites play a critical role in mediating protective cellular immunity.

Key words: immunologic memory • immunity • mucosal • paramyxovirus • CD4+ T lymphocytes

Introduction

CD4+ T lymphocytes play a major role in the immune responses to respiratory virus infections, such as those mediated by influenza and parainfluenza viruses, through the regulation of antibody production (1). In addition, it has also been established that CD4+ T lymphocytes, in association with CD8+ T cells, are involved in the cellular immune response to this class of infection, although the mechanisms are unclear (1–4). In general, primed memory CD4+ T cells accumulate more rapidly in the lung than naïve T cells and mediate accelerated virus clearance in immunocompetent mice (5). This protection is mediated at least in part by IFN-γ production and does not depend on antibody (references 4 and 6; unpublished observations). Although it is clear that CD4+ T cells play a role in protection, the recall of memory CD4+ T lymphocytes has generally been difficult to study, as the memory cells are present in the spleen at very low frequencies relative to CD8+ T cells. For example, CD4+ frequencies established to influenza and Sendai virus (a murine parainfluenza-1 virus) are typically in the range of 0.1% of CD4+ T cells in the spleen, whereas memory CD8+ T cells tend to be maintained at around 1–10% of CD8+ T cells (7–9). These memory CD4+ T cells persist at stable frequencies in the spleen and lymph nodes many months after the initial infection (7). However, the relative contribution of memory CD4+ T cells from different anatomical sites to protective cellular immune responses is unknown.

We have recently shown that memory CD8+ T cells persist in the lung tissue and airways for over 1 yr after recovery from a respiratory virus infection and that the numbers of cells present in the lungs correlates with the degree of protective immunity (10, 11). Lung memory CD8+ T cells express a highly activated phenotype and can be induced to proliferate and express various effector functions. Thus, we speculated that memory CD4+ T cell would also persist in the lung after resolution of the initial infection and that these cells would correlate with protective immunity. In this report, we show that functional memory CD4+ T cells persist at very high frequencies in the lungs after resolution of a Sendai virus infection. In addition, by intratracheal transfer of cells we show that these lung memory CD4+ T cells provide a substantial degree of protection against a secondary infection.

Address correspondence to D.L. Woodland, Trudeau Institute, P.O. Box 59, Saranac Lake, NY 12983. Phone: 518-891-3080; Fax: 518-891-5126; E-mail: dwoodland@trudeauinstitute.org
Materials and Methods

Viruses, Animals, and Infections. The Enders strain of Sendai virus and influenza virus A/HK-x31 (x31, H3N2) were grown, stored, and titrated as described previously (12, 13). Female C57BL/6, B6.129-Ptprca Pep3b/BoyJ (Ly5.1+), and C57BL/6-B2tmt1Unc (B2m-deficient) mice were purchased from the Animal Breeding Facility at the Trudeau Institute, The Jackson Laboratory, or Taconic Farms. Mice (6–12 wk) were anesthetized by intraperitoneal injection with 2,2,2 tribromoethanol and infected intranasally with 500 50% egg infectious doses (EID50) of Sendai virus or 300 EID50 of x31 influenza virus.


Tissue Preparation. Single cell suspensions were prepared from spleens and mediastinal lymph nodes (MLNs) by passage through cell strainers. Spleen cells were depleted of erythrocytes by treatment with buffered ammonium chloride solution. Bronchoalveolar lavage (BAL) cells were collected by lavage of the lungs 3–4 times with 1 ml of HBSS. Cells were prepared from lung tissue lavage (BAL) cells were collected by lavage of the lungs 3–4 times with 1 ml of HBSS. Cells were prepared from lung tissue by passing lavaged lungs through cell strainers. The cells were subsequently resuspended in 80% isotonic percoll and layered intranasally with 500 50% egg infectious doses (EID50) of Sendai virus or 300 EID50 of x31 influenza virus.

Enzyme-linked Immunospot Assay. The relative frequencies and numbers of IFN-γ-secreting cells derived from spleen, lung, MLN, and BAL tissues were determined after stimulation with Sen-HN421–436, Flu-HA192–207, Sen-NP324–332, or Flu-NP366–374 peptides in a standard enzyme-linked immunospot (ELISPOT) assay system. In brief, 96-well Multiscreen HA nitrocellulose plates (Millipore) were coated overnight at 4°C with 100 μl per well of rat anti–mouse IFN-γ (clone R4-6A2; BD PharMingen), at a concentration of 10 μg/ml. The plates were then washed and blocked before the addition of tiered numbers of responding cells, irradiated (3,000 rad) syngeneic spleen, peptide, and 10 U/ml rhIL-2. Plates were then incubated 24–48 h at 37°C and developed overnight with a biotinylated detection antibody, rat anti–mouse IFN-γ (clone XMG1.2; BD PharMingen), followed by streptavidin–horseradish peroxidase (Sav-HRP; BD PharMingen) for 2 h at room temperature. Visible spots of IFN-γ-secreting cells were then enumerated using an Olympus SZH stereo zoom microscope system. Absolute numbers of antigen-specific CD4+ T cells were calculated based on the number of live cells recovered per mouse tissue. The frequencies of antigen-specific T cells were determined by correcting the data for the number of CD4+ T cells put into the assay based on flow cytometric data. The number of spots in wells containing irrelevant peptides was below detection (<1 in 105).

Intracellular IFN-γ Staining. Cells isolated from the spleen, MLNs, lung tissue, and BAL (after plastic adherence) were mixed with naive spleen cells from Ly5.1+ H-2b mice. The cells were then cultured at 37°C for 5 h in the presence of 10 μg of the indicated peptide in 250 μl complete tumor medium (CTM) containing 10 μg/ml brefeldin A (BFA). After culture, the cells were blocked with monoclonal antibodies to FcRIII/II receptor and stained with anti–CD4–PE monoclonal antibodies. The data were acquired using a FACScan™ flow cytometer and analyzed with CELLQuest™ software (Becton Dickinson).
**Intratracheal Cell Transfer.** BAL cells were collected from C57BL/6 mice at >35 d after Sendai virus or influenza virus infection. The donor cells washed and resuspended in PBS at a concentration of 10^7 cells/ml. Naive C57BL/6 or β2m-deficient recipient mice were anesthetized and 100 μl (0.5–1 × 10^6 cells) of the cell suspension or PBS were instilled into the lungs (via the trachea) using a 1-ml syringe fitted with a blunt 20-G needle. Cells isolated from the BAL of mice that have recovered from a Sendai virus infection typically contain <0.5% B cells or plasma cells, as determined by flow cytometric analysis using antibodies specific for B220, CD19, and CD138.

**Results and Discussion**

**Activated CD4**+ **T Cells Persist in the Lungs After Resolution of a Primary Sendai Virus Infection.** To determine whether CD4+ T cells persisted in the lungs after recovery from a Sendai virus infection, we isolated cells from both the lung tissue and airways at day 41 after Sendai virus infection. Substantial numbers of CD4+ T cells were detected in both the lung tissue and airways, ranging from 30,000 to 100,000 cells per mouse lung (data not shown). Phenotypic analysis indicated that the CD4+ T cell populations in the spleen, MLNs, lung airways, and lung tissue displayed remarkably different phenotypes. As shown in Fig. 1, the vast majority of CD4+ T cells isolated from the BAL displayed high levels of CD44, low levels of CD62L, and low levels of Ly6C expression, indicating that they are predominantly “memory” T cells. In contrast, the levels of CD44 and CD62L expression in the lung tissue indicate that both naïve and “memory” CD4+ T cells are present at this site. As expected, the CD44/CD62L profile from the spleen and MLNs show a large number of naïve T cells (CD44highCD62Llow) and a much smaller number of antigen-experienced CD4+ T cells (CD44lowCD62Lhigh).

Analysis of the CD4+ T cells in the BAL showed that a large proportion of the cells were of a highly activated phenotype, characterized by the expression of acute activation markers, CD43 and CD69. In contrast, much lower frequencies of CD4+ T cells isolated from the lung tissue, MLNs, and spleen expressed CD43 and CD69. This difference in phenotype persisted even when CD44+CD44high “memory” T cells were analyzed separately. Thus, as shown in Table I, a large proportion of cells isolated from the BAL fluid possess an activate phenotype as indicated by CD43 and CD69 expression. In contrast, decreasing levels of activation marker expression were observed on CD4+CD44high “memory” T cells in the lung tissue, spleen, and MLNs. This pattern of activation marker expression is remarkable given that many weeks have passed since resolution of the primary infection and is very similar to the description of CD8+ memory T cells that persist in the lungs after recovery from Sendai or influenza virus infections (11). Although the activated phenotype of the cells in the lungs suggests that a pool of viral antigen may persist, we and others have been unable to demonstrate persistent viral antigen by PCR or by using a sensitive virus-specific hybridoma assay (data not shown; reference 14).

**Virus-specific Effector CD4**+ **T Cells Persist in the Lungs After Sendai Virus Infection.** To determine whether any of the CD4+ T cells that persisted in the lung were virus specific, we performed ELISPOT assays using cells isolated from the BAL, lung tissue, spleen, and MLNs of Sendai memory mice (day 41 after infection). The antigen used for these studies was a peptide representing an immunodominant I-Aβ-restricted epitope derived from the HN protein. Previous studies had shown that this epitope drives about 15% of the CD4+ T cell response to Sendai virus infection in the lung (reference 15; and data not shown). As shown in Table II, a substantial population of HN421–436/Aβ-specific CD4+ T cells, representing >13% of the total CD4+ T cell pool, is present in the BAL after resolution of the primary infection. Interestingly, the frequency of HN421–436/Aβ-specific CD4+ T cells in the lungs is much higher than the frequencies of HN421–436/Aβ-specific cells in the spleen and MLNs. For example the frequency of antigen-specific CD4+ T cells in the BAL is 200-fold higher than in the spleen (Table II). When absolute numbers of cells were compared, the population of virus-specific CD4+ T cells in the lungs (BAL and tissue) was more than twice the number isolated from the MLNs and ~20% of the number in the spleen. Phenotypic and ELISPOT analyses of cells isolated from the lungs of mice 90 d after Sendai virus infection showed similar results, indicating that antigen-specific CD4+ T cells persist in the lungs for >11 wk after infection.

As a control for these studies, we also determined the frequencies of CD8+ T cells in the lungs specific for the immunodominant NP324–332/Kb epitope by ELISPOT analysis (16). As expected, NP324–332/Kb-specific CD8+ T cells are present at very high frequencies and absolute numbers of mice intranasally infected with 500 EID50 Sendai virus and tissues were analyzed on day 34 after infection.

**Table I. The Proportion of CD4**+ **CD44**+ **T Cells Expressing the Indicated Markers After Sendai Virus Infection**

<table>
<thead>
<tr>
<th></th>
<th>BAL</th>
<th>Lung tissue</th>
<th>MLNs</th>
<th>Spleen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent CD44+</td>
<td>82</td>
<td>36</td>
<td>25</td>
<td>26</td>
</tr>
<tr>
<td>among CD4+</td>
<td>6</td>
<td>15</td>
<td>19</td>
<td>28</td>
</tr>
<tr>
<td>CD62L+</td>
<td>72</td>
<td>63</td>
<td>19</td>
<td>28</td>
</tr>
<tr>
<td>CD43+</td>
<td>40</td>
<td>17</td>
<td>27</td>
<td>33</td>
</tr>
<tr>
<td>CD69+</td>
<td>23</td>
<td>9</td>
<td>33</td>
<td>28</td>
</tr>
<tr>
<td>CD25+</td>
<td>13</td>
<td>20</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Ly6C+</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Mice were intranasally infected with 500 EID50 Sendai virus and tissues were analyzed on day 34 after infection.

*Data were generated by pooling cells isolated from the indicated number of mice.
bers in the lung airways and lung tissue at day 41 after Sendai virus infection (Table II), consistent with previous reports (11). As an additional control, we also included an influenza peptide representing a dominant I-Ab epitope (HA421–436/Ab). This peptide was always negative (i.e., frequencies of \( \leq 1:1 \times 10^6 \)) in these ELISPOT assays (data not shown). Taken together, these data show that high frequencies of antigen-specific memory CD4\(^+\) T cells persist in the lungs after recovery from a Sendai virus infection and that these cells can be induced to secrete IFN-\(\gamma\) in a 48-h restimulation (ELISPOT) assay.

Having established that activated virus-specific CD8\(^+\) and CD4\(^+\) T cells persist in the lungs, we next investigated the ability of both populations to produce IFN-\(\gamma\) directly ex vivo using an intracellular cytokine assay. Cells were isolated from the lung airways of Sendai memory mice (40 d after infection) by lavage and restimulated for 5 h in vitro in the presence of BFA, peptide, IL-2, and Ly5.1\(^+\) spleen cells. Ly5.1\(^+\) spleen cells were used as APCs to allow us to specifically examine IFN-\(\gamma\)-production in the BAL cell population (Ly5.2\(^+\)). As shown in Fig. 2, stimulation with PMA and ionomycin induced IFN-\(\gamma\)-production in \(\sim 15\%\) of both CD4\(^+\) and CD8\(^+\) T cells. Furthermore, significant populations of CD4\(^+\) and CD8\(^+\) BAL cells also produced IFN-\(\gamma\) after stimulation with the relevant Sendai virus peptides. In contrast, memory cells cultured with irrelevant control peptides corresponding to the CD4 and CD8 immunodominant epitopes of influenza virus produced only background levels of IFN-\(\gamma\) (Fig. 2). Staining with an isotype control antibody also confirmed the specificity of the assay. In additional experiments, BAL cells were labeled with carboxyfluorescein diacetate-succinimidyl ester

### Table II. ELISPOT Analysis of Virus-specific T Cells in the BAL, Lung Tissue, MLNs, and Spleens of C57BL/6 Mice After Resolution of a Primary Sendai Virus Infection

<table>
<thead>
<tr>
<th></th>
<th>Sendai HN(_{421-436}) specific among CD4(^+)</th>
<th>Total no. of Sen-HN(_{421-436})-specific cells per mouse</th>
<th>Sendai NP(_{324-332}) specific among CD8(^+)</th>
<th>Total no. of Sen-NP(_{324-332})-specific cells per mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAL ((n = 9*))(^*)</td>
<td>13.2</td>
<td>1,964</td>
<td>59.5</td>
<td>11,032</td>
</tr>
<tr>
<td>Lung tissue ((n = 8))</td>
<td>2.1</td>
<td>1,679</td>
<td>13.9</td>
<td>7,400</td>
</tr>
<tr>
<td>MLNs ((n = 8))</td>
<td>0.11</td>
<td>1,512</td>
<td>0.37</td>
<td>4,992</td>
</tr>
<tr>
<td>Spleen ((n = 3))</td>
<td>0.06</td>
<td>18,320</td>
<td>0.44</td>
<td>88,578</td>
</tr>
</tbody>
</table>

Mice were intranasally infected with 500 EID\(_{50}\) Sendai virus and tissues were analyzed on day 41 after infection. Data are representative of two independent experiments.

\(^*\)Data were generated by pooling cells isolated from the indicated number of mice.

Figure 2. BAL memory cells produce IFN-\(\gamma\) directly ex vivo. Cells were isolated from the lung airways (BAL) of mice that had recovered from Sendai virus infection (day 34). The cells were restimulated with PMA/ionomycin or Sen-HN\(_{421-436}\)/Flu-HA\(_{192-207}\)/Sen-NP\(_{324-332}\) or Flu-NP\(_{366-374}\) peptides in the presence of BFA, IL-2, and lymph node Ly5.1\(^+\) spleen cells as APCs. After 5 h in culture, all cells were stained with anti-Ly5.2 biotin followed by streptavidin-allophycocyanin and the indicated antibodies. The data are presented as live Ly5.2\(^+\) lymphocytes (BAL). The numbers indicate the percentages of IFN-\(\gamma\)-secreting cells among the total Ly5.2\(^+\)CD8\(^+\) cells (BAL). The numbers indicate the percentages of IFN-\(\gamma\)-secreting cells among the total Ly5.2\(^+\)CD8\(^+\) cell population. Data are representative of three independent experiments.
Published April 16, 2001

Significant as based on a standard test. The data are expressed as log_{10} EID_{50} and are representative of three independent experiments.

**Figure 3.** BAL memory cells confer protection against Sendai virus infection. (A) 10 naive C57BL/6 mice were intranasally infected with 500 EID_{50} Sendai virus. 4 h before infection, the mice received either memory BAL cells (5 × 10^{6} cells in 100 μl, n = 5), or control PBS (100 μl, n = 5) intratracheally. The BAL cells in this experiment were derived from C57BL/6 mice that had recovered from infection with 500 EID_{50} Sendai virus (35 d after infection). (B) 16 naïve β2m-deficient mice were intranasally infected with 500 EID_{50} Sendai virus. 4 h before infection, each mouse received either Sendai memory BAL cells (10^{6} cells in 100 μl, n = 6), influenza memory BAL cells (10^{6} cells in 100 μl, n = 6), or control PBS (100 μl, n = 4) intratracheally. In this experiment, Sendai memory BAL cells were obtained from C57BL/6 mice at day 40 after infection, whereas influenza memory BAL cells were obtained from C57BL/6 mice at day 41 after infection. In both A and B, virus titers in the lungs were determined 4 d after transfer by titrating lung homogenates in embryonated chicken eggs, followed by hemagglutination assays. Where indicated, the difference in viral titers among each group was determined to be statistically significant as based on a standard t test. The data are expressed as log_{10} EID_{50} and are representative of three independent experiments.

*CD4^+ Cells in the Lung Airways Can Mediate Protective Immunity.*

The mechanism by which CD4^+ T cells mediate protection against respiratory virus infections is unclear. However, there is substantial evidence that IFN-γ production is a key player in this protection. In this regard, the presence of both CD4^+ and CD8^+ T cells in the lungs capable of rapidly producing IFN-γ is consistent with the idea that this cytokine plays a critical role. The absolute numbers of antigen-specific CD4^+ T cells in the lung is relatively small (~20% of the number in the spleen; Table II). But these cells are present in a highly activated state and are able to respond immediately at the site of infection when the viral load is still very low. Thus, a relatively small number of cells may be sufficient to have a significant impact on the early stages of the infection, especially if the cells proliferate and mediate sustained cytokine production. In addition, these cells may function to rapidly recruit other inflammatory cells to the site of infection through the production of chemokines. We have also shown that the development of an effective CD4^+ T cell response depends on the presence of CD8^+ T cells, suggesting a regulatory role for CD8^+ T cells (unpublished observations). It should be noted that both CD4^+ and CD8^+ T cells were physically present in the intratracheal transfer experiments that demonstrated protective immunity, but that the CD8^+ T cell function was significantly impaired due to a deficient H-2Kb expression on the host respiratory epithelium.

It is currently unclear how memory cells persist in the lung tissues and airways. Based on observations with the CD8^+ memory T cells, we have speculated that memory CD4^+ and CD8^+ cells in the spleen are slowly dividing and that some of the activated cells enter the circulation (10, 11). Given the activated phenotype of these cells, they are likely to accumulate in mucosal tissues, including the lung and lung airways. For example, there is substantial evidence that activated T cells accumulate in the lung and extravasate across epithelium into the airways (19). The absolute...
number of cells in the lung would depend on the relative numbers and replication rates of memory cells in secondary lymphoid organs that seed the circulation, and the length of time that the cells persist at mucosal sites. In support of this general idea, we have shown that vaccination protocols that do not involve infection of the lung nevertheless induce substantial populations of memory CD4+ and CD8+ T cells in the lungs (data not shown).

Taken together, the data demonstrate that memory CD4+ T cells with an activated phenotype and capable of immediate effector function persist at very high frequencies in the lungs after resolution of a respiratory virus infection, and that these cells are capable of mediating protective cellular immunity. These findings have significant implications for our understanding of cellular immunity to infection and vaccine development.

We would like to thank Simon Monard for assistance with the flow cytometry, Jean Brennan for help with the intratracheal transfers, and Dr. Marcy Blackman for critically reviewing the manuscript.

This work was supported by funds from the Trudeau Institute and National Institutes of Health grants F32 AI10590 (R.J. Hogan), R01 AI37597 (D.L. Woodland), and R01 HL63925 (D.L. Woodland).

Submitted: 29 December 2000
Revised: 23 February 2001
Accepted: 7 March 2001

References